Monopar Therapeutics Inc. Financing Cash Flow
Monopar Therapeutics Inc. (MNPR) reported Financing Cash Flow of -$847.59 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$647.39K.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$200.20K.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$384.68K, a 100.69% decline year-over-year.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $92.39M.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $91.57M, a 54.45% increase from fiscal 2024.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $59.29M, a 2824.80% increase from fiscal 2023.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $2.03M, a 6066.85% increase from fiscal 2022.
- Monopar Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $32.87K, a 99.70% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$647.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$847.59K 10-Q · filed 2026-08-12 | -$1.23M derived: sum of 3 quarters · filed 2026-08-12 | $91.16M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$200.20K 10-Q · filed 2026-05-14 | -$584.88K derived: sum of 2 quarters · filed 2026-05-14 | $91.81M derived: sum of 3 quarters · filed 2026-05-14 | $91.49M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$384.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $92.01M derived: sum of 2 quarters · filed 2026-03-27 | $91.69M derived: sum of 3 quarters · filed 2026-08-12 | $91.57M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $92.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $92.07M derived: sum of 2 quarters · filed 2026-08-12 | $91.96M 10-Q · filed 2025-11-13 | $148.10M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$316.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$432.53K 10-Q · filed 2026-08-12 | $55.70M derived: sum of 3 quarters · filed 2026-08-12 | $55.69M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$115.68K 10-Q · filed 2026-05-14 | $56.02M derived: sum of 2 quarters · filed 2026-05-14 | $56.00M derived: sum of 3 quarters · filed 2026-05-14 | $55.99M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $56.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $56.12M derived: sum of 2 quarters · filed 2026-03-27 | $56.11M derived: sum of 3 quarters · filed 2026-03-27 | $59.29M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$16.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$26.45K derived: sum of 2 quarters · filed 2025-11-13 | $3.16M 10-Q · filed 2025-11-13 | $3.49M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$9.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.17M 10-Q · filed 2025-08-12 | $3.51M derived: sum of 3 quarters · filed 2025-08-12 | $3.75M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.18M 10-Q · filed 2025-05-13 | $3.52M derived: sum of 2 quarters · filed 2025-05-13 | $3.76M derived: sum of 3 quarters · filed 2025-05-13 | $4.40M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $334.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $581.25K derived: sum of 2 quarters · filed 2025-03-31 | $1.22M derived: sum of 3 quarters · filed 2025-03-31 | $2.03M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $246.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $887.88K derived: sum of 2 quarters · filed 2024-08-09 | $1.69M 10-Q · filed 2023-11-09 | $1.83M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-06-30 | $641.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.45M 10-Q · filed 2024-08-09 | $1.58M derived: sum of 3 quarters · filed 2024-08-09 | $1.56M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | $804.80K 10-Q · filed 2024-05-09 | $943.53K derived: sum of 2 quarters · filed 2024-05-09 | $919.80K derived: sum of 3 quarters · filed 2024-05-09 | $854.34K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $138.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $115.00K derived: sum of 2 quarters · filed 2024-03-28 | $49.54K derived: sum of 3 quarters · filed 2024-03-28 | $32.87K 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$23.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$89.20K derived: sum of 2 quarters · filed 2023-11-09 | -$105.86K 10-Q · filed 2023-11-09 | -$113.64K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$65.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$82.13K 10-Q · filed 2023-08-10 | -$89.90K derived: sum of 3 quarters · filed 2023-08-10 | -$99.88K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$16.67K 10-Q · filed 2023-05-11 | -$24.44K derived: sum of 2 quarters · filed 2023-05-11 | -$34.42K derived: sum of 3 quarters · filed 2023-05-11 | -$58.42K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$7.77K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$17.75K derived: sum of 2 quarters · filed 2023-03-23 | -$41.75K derived: sum of 3 quarters · filed 2023-03-23 | $10.88M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$9.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$33.98K derived: sum of 2 quarters · filed 2022-11-10 | $10.89M 10-Q · filed 2022-11-10 | $10.88M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $10.90M 10-Q · filed 2022-08-11 | $10.89M derived: sum of 3 quarters · filed 2022-08-11 | $17.62M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $10.92M 10-Q · filed 2022-05-12 | $10.91M derived: sum of 2 quarters · filed 2022-05-12 | $17.65M derived: sum of 3 quarters · filed 2022-05-12 | $18.60M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$7.14K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $6.73M derived: sum of 2 quarters · filed 2022-03-24 | $7.67M derived: sum of 3 quarters · filed 2022-03-24 | $8.18M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $6.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $7.68M derived: sum of 2 quarters · filed 2021-11-12 | $8.19M 10-Q · filed 2021-11-12 | $17.58M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $946.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.45M 10-Q · filed 2021-08-12 | $10.84M derived: sum of 3 quarters · filed 2021-08-12 | $10.83M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $508.04K 10-Q · filed 2021-05-13 | $9.89M derived: sum of 2 quarters · filed 2021-05-13 | $9.88M derived: sum of 3 quarters · filed 2021-05-13 | $9.87M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $9.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $9.37M derived: sum of 2 quarters · filed 2021-03-25 | $9.36M derived: sum of 3 quarters · filed 2021-03-25 | $9.35M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$13.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$25.60K derived: sum of 2 quarters · filed 2020-11-12 | -$39.46K 10-Q · filed 2020-11-12 | -$245.73K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$12.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$26.18K 10-Q · filed 2020-08-06 | -$232.45K derived: sum of 3 quarters · filed 2020-08-06 | -$232.45K derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$13.86K 10-Q · filed 2020-05-07 | -$220.13K derived: sum of 2 quarters · filed 2020-05-07 | -$220.13K derived: sum of 3 quarters · filed 2020-05-07 | -$220.13K derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$206.27K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$206.27K derived: sum of 2 quarters · filed 2020-03-27 | -$206.27K derived: sum of 3 quarters · filed 2020-03-27 | -$206.27K 10-K · filed 2020-03-27 | $0.00 10-K · filed 2019-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | $10.00K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $10.00K derived: sum of 3 quarters · filed 2019-08-08 | $7.51M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-10 | $10.00K derived: sum of 2 quarters · filed 2019-05-10 | $7.51M derived: sum of 3 quarters · filed 2019-05-10 | $8.55M derived: sum of 4 quarters · filed 2019-05-10 | |
| 2017-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $7.51M derived: sum of 2 quarters · filed 2019-02-26 | $8.55M derived: sum of 3 quarters · filed 2019-02-26 | $9.54M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $8.54M derived: sum of 2 quarters · filed 2018-11-09 | $9.53M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.03M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $990.00K 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | $1.26M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |